A detailed history of Alps Advisors Inc transactions in Celcuity Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 20,391 shares of CELC stock, worth $1.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,391
Previous 28,798 29.19%
Holding current value
$1.4 Million
Previous $291,000 6.53%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 11, 2025

SELL
$8.21 - $13.35 $69,021 - $112,233
-8,407 Reduced 29.19%
20,391 $272,000
Q1 2025

Apr 30, 2025

SELL
$8.62 - $13.62 $10,602 - $16,752
-1,230 Reduced 4.1%
28,798 $291,000
Q4 2024

Feb 13, 2025

SELL
$12.0 - $16.35 $780 - $1,062
-65 Reduced 0.22%
30,028 $393,000
Q3 2024

Nov 12, 2024

BUY
$13.98 - $19.15 $37,941 - $51,973
2,714 Added 9.91%
30,093 $448,000
Q2 2024

Aug 13, 2024

BUY
$14.1 - $20.78 $386,043 - $568,935
27,379 New
27,379 $448,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $1.02B
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.